Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2013-01-03 18:54:43
Reporting Period:
Filing Date:
Accepted Time:
2013-01-03 18:54:43
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1339455 Somaxon Pharmaceuticals Inc. SOMX Pharmaceutical Preparations (2834) 200161599
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1457013 Tran Nguyen Somaxon Pharmaceuticals, Inc.
440 Stevens Avenue, Suite 200
Solana Beach CA 92075
Svp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-12-31 1,494 $0.00 50,361 No 4 A Direct
Common Stock Disposition 2013-01-02 412 $3.08 49,949 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
  1. These RSUs were granted in lieu of a portion of the Participant's salary from the quarter ended December 31, 2012. Subject to the terms of the Restricted Stock Unit Agreement, 100% of the RSU Award shall vest upon the earlier of (a) the time that is immediately prior to the consummation of the merger contemplated by the Agreement and Plan of Merger by and among the Company, Pernix Therapeutics Holdings, Inc. and Pernix Acquisition Corp. I dated as of December 10, 2012 (the "Merger Agreement"), or (b) the first date included within an open trading window under the Company's Insider Trading Policy following any termination of the Merger Agreement, subject in either case to Participant's continued status as an Employee, Independent Director or Consultant (each as defined in the Plan) of the Company or any Subsidiary on such vesting date.
  2. This sale was effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.